{"log_id": 1698764936759235020, "direction": 0, "words_result_num": 35, "words_result": [{"probability": {"variance": 0.009896, "average": 0.962611, "min": 0.539006}, "location": {"width": 808, "top": 252, "height": 25, "left": 241}, "words": "在两个组别各个不同的治疗阶段,血清门冬酰胺浓度都是在门冬酰按酶给药后4日内下降,并且在"}, {"probability": {"variance": 0.027618, "average": 0.923196, "min": 0.371496}, "location": {"width": 849, "top": 284, "height": 23, "left": 201}, "words": "随3周门冬酰胶仍保持低浓度。药物治疗诱期血清中门冬酰胺的浓度见图1、在强化治疗期门冬"}, {"probability": {"variance": 0.019407, "average": 0.953803, "min": 0.407768}, "location": {"width": 406, "top": 314, "height": 25, "left": 201}, "words": "耗竭的模式和诱导期药物耗竭的模式是似的"}, {"probability": {"variance": 0.000589, "average": 0.991256, "min": 0.895984}, "location": {"width": 465, "top": 371, "height": 28, "left": 394}, "words": "图1:研究1血清中门冬酰胺酸的浓度一时间关系"}, {"probability": {"variance": 0, "average": 0.975731, "min": 0.975731}, "location": {"width": 176, "top": 554, "height": 87, "left": 652}, "words": "针"}, {"probability": {"variance": 0.01144, "average": 0.960931, "min": 0.592879}, "location": {"width": 200, "top": 792, "height": 25, "left": 198}, "words": "注意:培门冬酶的剂量为25"}, {"probability": {"variance": 0.011429, "average": 0.970002, "min": 0.501328}, "location": {"width": 574, "top": 793, "height": 23, "left": 476}, "words": "于为期4周的诱导期第3天进行肌肉注射天然大肠杆菌左旋门冬酰胺酶给药剂"}, {"probability": {"variance": 0, "average": 0.998937, "min": 0.998736}, "location": {"width": 33, "top": 825, "height": 20, "left": 199}, "words": "量为"}, {"probability": {"variance": 0.000787, "average": 0.988884, "min": 0.876832}, "location": {"width": 301, "top": 823, "height": 24, "left": 327}, "words": "在诱导期每周给药3次,连续3周共9次"}, {"probability": {"variance": 0.001843, "average": 0.984391, "min": 0.798161}, "location": {"width": 758, "top": 850, "height": 27, "left": 287}, "words": "例诱导期患者脑脊液中门冬酰胺浓度进行了检测。脑脊液中门冬酰胺从给药前3.1μM下降"}, {"probability": {"variance": 0, "average": 0.999085, "min": 0.999085}, "location": {"width": 21, "top": 886, "height": 22, "left": 199}, "words": "到"}, {"probability": {"variance": 0.005797, "average": 0.961151, "min": 0.711916}, "location": {"width": 696, "top": 879, "height": 26, "left": 349}, "words": "第4±1天的1.7uM,第21±1天的1.5μM。这些情况和天然大肠杆菌左旋门"}, {"probability": {"variance": 0.006365, "average": 0.973021, "min": 0.521804}, "location": {"width": 834, "top": 912, "height": 25, "left": 208}, "words": "冬酰胺酶给药后是类似的。两个给药组3年无事件生存期约为80%,结果类似。该研究方案中事先没"}, {"probability": {"variance": 4e-06, "average": 0.99841, "min": 0.992778}, "location": {"width": 270, "top": 943, "height": 23, "left": 199}, "words": "有设计评价无事件生存期的差别"}, {"probability": {"variance": 4e-06, "average": 0.998577, "min": 0.992955}, "location": {"width": 293, "top": 972, "height": 27, "left": 236}, "words": "对门冬酰胺酶高敏的患者临床研究"}, {"probability": {"variance": 0.000115, "average": 0.995437, "min": 0.947913}, "location": {"width": 812, "top": 1002, "height": 25, "left": 236}, "words": "在4项开放的研究中,包括了42名对左旋门冬酰胺酶产生临床过敏、多次复发的急性白血病患者"}, {"probability": {"variance": 0.006135, "average": 0.982678, "min": 0.492106}, "location": {"width": 835, "top": 1032, "height": 25, "left": 212}, "words": "39%为急性淋巴细胞白血病),对 Oncaspar的安全性和有效性进行了评价。对左旋门冬酰胺酶高敏"}, {"probability": {"variance": 0.006486, "average": 0.977839, "min": 0.498572}, "location": {"width": 836, "top": 1062, "height": 26, "left": 198}, "words": "的定义为天然大肠杆菌左旋门冬酰胺酶给药后产生企身性皮疹、风疹、支气管痉挛、喉水肿、低血压"}, {"probability": {"variance": 0.00347, "average": 0.986823, "min": 0.617357}, "location": {"width": 843, "top": 1093, "height": 26, "left": 198}, "words": "局部红斑或肿胀,大于2公分,持续至少10分钟。所有接受 Oncaspar治疗的患者进行肌肉或静脉注"}, {"probability": {"variance": 0.006774, "average": 0.958209, "min": 0.602191}, "location": {"width": 456, "top": 1125, "height": 24, "left": 195}, "words": "射,剂量为2000,2500IU/m2,每14天给药1次。Or"}, {"probability": {"variance": 0.001974, "average": 0.980737, "min": 0.852855}, "location": {"width": 323, "top": 1124, "height": 23, "left": 712}, "words": "作为单药治疗或者联合治疗的一个组份"}, {"probability": {"variance": 0.001656, "average": 0.988012, "min": 0.717377}, "location": {"width": 828, "top": 1154, "height": 27, "left": 199}, "words": "再次诱导治疗的总反应率为50%(95%的可信区间为35%~65%),36%完全缓解,14%部分缓解"}, {"probability": {"variance": 0.004365, "average": 0.985217, "min": 0.559467}, "location": {"width": 852, "top": 1185, "height": 26, "left": 196}, "words": "这个结果与急性淋巴细胞白血病患者接受含大肠杆菌左旋门冬酰胺酶的联食二线化疗的总反应率是类"}, {"probability": {"variance": 0.003879, "average": 0.978856, "min": 0.646639}, "location": {"width": 849, "top": 1215, "height": 26, "left": 199}, "words": "似的。 Naspa单药治疗也观察到抗肿瘤活性。在9个复发的或对天然大肠杆菌左旋门冬酰胺酶高敏"}, {"probability": {"variance": 0.000102, "average": 0.995111, "min": 0.959508}, "location": {"width": 778, "top": 1246, "height": 27, "left": 199}, "words": "的成人和儿童急性淋巴性白血病患者中,有3个患者产生反应(1个完全缓解,2个部分缓解"}, {"probability": {"variance": 5e-06, "average": 0.998272, "min": 0.993018}, "location": {"width": 135, "top": 1279, "height": 22, "left": 236}, "words": "◇国内临床研究"}, {"probability": {"variance": 0.000144, "average": 0.994721, "min": 0.931239}, "location": {"width": 812, "top": 1306, "height": 26, "left": 234}, "words": "在中国儿童患者中进行了一项多中心、单窗、随机、阳性对照的临床研究。共入组131例初治的"}, {"probability": {"variance": 0.002622, "average": 0.984107, "min": 0.705719}, "location": {"width": 853, "top": 1334, "height": 30, "left": 196}, "words": "标危及高危的儿童急性淋巴细胞血瘫患者,男性84例,女性47例,年龄3~18岁,随机分为培门"}, {"probability": {"variance": 0.007102, "average": 0.976814, "min": 0.478644}, "location": {"width": 850, "top": 1367, "height": 26, "left": 197}, "words": "冬酶联合化疗试验组(简称试验组)和天然的左旋门冬酰胺酶联合化疗对照组(简称对照组)。试验组"}, {"probability": {"variance": 0.001186, "average": 0.991559, "min": 0.763707}, "location": {"width": 850, "top": 1397, "height": 27, "left": 196}, "words": "65例,对照组66例,依《血液学诊断及疗效标准》(第二版张之南)进行诊断和疗效判定。培门冬酶"}, {"probability": {"variance": 0.002279, "average": 0.98011, "min": 0.727407}, "location": {"width": 839, "top": 1429, "height": 26, "left": 196}, "words": "的剂量为2500IU/m2,第10,24天肌肉注射给药,左旋门冬酰胺酶的剂量为6000U/m2,第10,12"}, {"probability": {"variance": 0.003125, "average": 0.978491, "min": 0.691068}, "location": {"width": 779, "top": 1460, "height": 25, "left": 267}, "words": "8,20天静脉滴注给药;均联合长春新碱、泼尼松、及柔线霉素(柔红霉素,静脉滴注,30mg"}, {"probability": {"variance": 0.004751, "average": 0.974093, "min": 0.574165}, "location": {"width": 837, "top": 1488, "height": 29, "left": 198}, "words": "m2次,第8、9天给药,标危组共2次,高危组共4次;长春新碱,最大2mg静脉滴注,2mg/m3次"}, {"probability": {"variance": 0.005353, "average": 0.976691, "min": 0.510321}, "location": {"width": 845, "top": 1520, "height": 27, "left": 196}, "words": "第8、15、22、29天给药共4次;泼尼松,口服,40mg/m2,最大60mg/d,第1-35天给药,共4周)"}, {"probability": {"variance": 0.000155, "average": 0.99426, "min": 0.941653}, "location": {"width": 526, "top": 1553, "height": 25, "left": 195}, "words": "结果试验组与对照组间缓解率比较,差异无统计学意(见表4)"}], "language": 3}